Psychopharmacologic treatment of attention-deficit/hyperactivity disorder and disruptive behavior disorders.
Newcorn
Jeffrey H
JH
Mount Sinai School of Medicine, New York, USA.
Ivanov
Iliyan
I
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D019958:Attention Deficit and Disruptive Behavior Disorders / Q000188:drug therapy* / Q000503:physiopathology; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D019955:Conduct Disorder / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000077408:Modafinil; D009446:Neurobiology; D010372:Pediatrics; D011437:Propylamines / Q000627:therapeutic use; D011600:Psychopharmacology / Q000379:methods*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D014481:United States
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D000069445:Atomoxetine Hydrochloride; D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D000077408:Modafinil; D011437:Propylamines; D017367:Selective Serotonin Reuptake Inhibitors